Fact vs. Fiction: Watch Dr. SHUT DOWN This CNN Anchor On Live TV Over Abortion Pill Risks - See The Video Here

By Lisa Pelgin | Saturday, 30 March 2024 01:45 AM
2
Views 4.5K

During a recent segment on CNN, anchor Kaitlan Collins engaged in a discussion with Dr. Christina Francis, an ob-gyn, and Alliance Defending Freedom attorney Kristen Waggoner regarding the safety of abortion pills, particularly mifepristone.

The conversation took a turn when Collins attempted to challenge the expertise of Dr. Francis, only to be met with a factual correction.

Collins insinuated that Dr. Francis lacked experience in treating women with complications from mifepristone, to which Dr. Francis promptly clarified by recounting instances where she had provided care to women facing complications from the drug.

Dr. Francis highlighted the increasing frequency of cases where women require emergency room visits due to incomplete abortions initiated by these drugs, emphasizing the lack of in-person medical supervision prior to their administration.

 DON JR. OUTSIDE THE COURTHOUSE: "YOU HAVE A RIGGED SYSTEM"bell_image

Waggoner further dismantled Collins' argument by referencing the FDA's own data, which contradicted Collins' assertion of mifepristone's safety. Waggoner pointed out that the FDA's label for mifepristone acknowledges that a significant percentage of women may require emergency room visits and surgical interventions after taking the drug.

 WATCH: STEP-BY-STEP ANNIHILATION OF BLINKEN BY TED CRUZbell_image

She underscored the necessity of in-person medical consultations before undergoing the process of inducing labor at home with abortion pills.

Despite Collins' claim that mifepristone is safer than penicillin, Waggoner reiterated the FDA's findings, emphasizing the prevalence of severe complications among women using the drug.

 CASH FOR THE PAST: CALIFORNIA MAKES DICEY MOVEMENT ON REPARATIONS BILLSbell_image

She highlighted the FDA's stance that in-person doctor visits are crucial and minimally burdensome for patients, citing thousands of cases where women experienced severe complications post-mifepristone consumption.

Waggoner emphasized that the FDA's own data contradicted the notion of mifepristone's safety, pointing out the significant percentage of women requiring surgical interventions and facing severe complications. She underscored the disparity between the FDA's statements in court and its documented findings, challenging the narrative of mifepristone's safety perpetuated by Collins.

 CAUGHT AT THE BORDER: CBP'S NEW REPORT IS SCARY AS SH*Tbell_image

Collins' arguments lacked substantiation, particularly concerning the safety of abortion pills. The FDA's evolving regulations on mifepristone, from stringent reporting requirements to relaxed restrictions based on perceived low adverse effects, underscore the complexity and controversy surrounding the drug's safety profile.

 LARA TRUMP'S POWER PLAY: GAME-CHANGING APPROACH TO RESHAPE THE RNCbell_image

The exchange on CNN shed light on the ongoing legal battle challenging the FDA's approval of mifepristone and the necessity of informed medical supervision for women considering its use. The differing perspectives presented by Dr. Francis and Waggoner highlighted the nuanced debate surrounding abortion pills and the imperative of evidence-based discussions on women's reproductive health.

X